ERBB2 and breast cancer: At variance, Ji and colleagues demonstrate that miR-29b-3p promotes sensitivity of luminal or HER2-positive breast cancer cells to Palbociclib [33], a selective inhibitor of CDK4 and CDK6 kinases, which could prevent progression of the cell cycle from G1 into the S phase in various tumors [89].